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Ian Caterson,1 Nick Finer,2 Louise A Baur3,and Kate Steinbeck4
Obesity treatment aims to produce weight loss and weight-loss maintenance, as well as 
risk reduction, disease prevention, amelioration or cure. Treatment needs to be designed 
according to the person’s need. A small loss (5%–10% of initial body weight) may suffice for 
disease prevention, but greater weight loss is often needed for mobility or for disease cure in 
those with a greater degree of obesity. For children and adolescents, family involvement and 
a developmentally appropriate approach are vital. For example, for pre-pubertal children, 
who are still growing in height, reduction in the rate of weight gain, or weight stability, 
may be sufficient to achieve health improvement. Lifestyle interventions to achieve energy 
restriction and increase energy expenditure (through activity and exercise) are the initial 
approach. Pharmacotherapy can improve the efficacy of lifestyle interventions. Intragastric 
devices and bariatric surgery may be appropriate for those with more severe disease, 
including selected older adolescents. While weight loss can be achieved, the major issue 
in treatment of obesity remains weight maintenance and efforts need to be directed to this 
end.
Overweight and obesity are common in Australia, with approximately one in five adults 
being obese, two in five overweight and approximately one in four of our children being 
overweight or obese. This condition has essentially become the norm. As is discussed 
elsewhere in this volume, this increasing obesity prevalence has come with increasing 
health problems and diseases. Whilst many of these diseases can be treated directly (and 
at continuing expense) it would be better to prevent such obesity-associated diseases by 
treating their underlying cause, that is by managing overweight and obesity properly. In 
fact, it would be even better to prevent overweight and obesity occurring in our society!
Traditionally the health professionals have been pessimistic about their ability to treat 
obesity but with the new realisations of what successful treatment really is, and with the 
newer treatment modalities, obesity treatment can be, and is, successful. What is needed 
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is a practical approach, individual goals for each patient and a system which provides the 
appropriate intervention as well as continuing support and follow-up. These aspects of 
obesity management for adults, adolescents and children will be discussed in the chapter.
Management of obesity in adults: whom to treat and how to treat?
There are a number of modalities involved in the management of obesity, which should be 
delivered as an integrated program. These modalities include standard lifestyle interventions 
(eating and activity), behaviour and group therapy, adjunctive therapy (pharmacotherapy, 
meal replacement regimes), some special devices (intragastric balloons) and bariatric 
surgery. A suggested approach utilising the patient’s body mass index (BMI, weight/height2, 
kg/m2), the presence of obesity-associated comorbidities, and a range of treatment options 
is outlined in Table 1.
Table 1. A management approach for obesity in adults. 
BMI (kg/m2)* Lifestyle** Obesity 
drugs
VLEDs Devices: eg 
intragastric 
balloon
Bariatric 
surgery
25 to 26.9 Advice
27 to 34.9 Lifestyle 
program
Consider Possibly
27 to 34.9 
±comorbidity
Lifestyle 
program
Consider Probably Possibly
>35 
±comorbidity
Lifestyle 
program
Consider Utilise Possibly Consider
>40 (if no 
comorbidities)
Lifestyle 
program
Consider Utilise Possibly Consider
* If there is increased waist circumference (the importance of which is described elsewhere in this 
volume) then a more intensive therapeutic regimen may be utilised at a lower BMI range. 
** All the components of the lifestyle program and other therapies are described below. Obesity 
pharmacotherapy may be utilised to help maintain weight after it is lost using other treatment 
modalities instead of just being used to produce weight loss. Very low energy diets (VLEDs) are useful 
for initiating and obtaining weight loss, in weight maintenance and prior to bariatric surgery.
It is important that healthcare practitioners recognise when a patient has a weight problem 
and for them to be able to prescribe an appropriate management plan for the patient’s 
degree of obesity, life stage and situation.
Lifestyle management
A lifestyle-management program remains the basis of all obesity treatment [1]. Such a 
program has a number of components, the most obvious of which are eating and physical 
activity plans. Another major component is a behaviour-modification program. Other 
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aspects include goal setting, psychological support (and counselling if necessary), proper 
medical management and a long-term plan for maintaining weight loss. Such lifestyle 
programs have been shown to be effective [2], and losses of 6% or more of initial body 
weight can be achieved and maintained. There is no reason for such programs to be 
delivered solely by health professionals [3]. For those with a BMI in the lower overweight 
and obesity range (ie BMI 27 to 34.9 kg/m2), and without major medical complications, 
such programs can be delivered effectively in the community setting.
Goal setting
This is often ignored, or not specifically discussed with the patient. The goals will vary 
from patient to patient. It is important to set realistic goals for weight loss, of course, but 
other goals may be individual and/or medical. Other than weight loss, goals may include 
prevention and control of disease (such as diabetes), better mobility, less medications, 
ability to have a joint replacement, or a specific goal that the patient wants to achieve. Such 
goals should be discussed, recorded and when reached the achievement should be noted 
and the patient congratulated.
Eating 
It is better to use the term ‘eating plan’ rather than ‘diet’. Diets tend to be seen as short term 
and there are many which are pushed by magazines, in books, and online, and there is a 
large industry producing these diet plans. This plethora of diets is confusing and unhelpful 
for someone attempting to lose and then maintain weight loss. It has been shown that the 
amount of weight loss obtained does not depend on the type of eating plan prescribed; 
most produce similar weight losses at six months with gradual weight regain thereafter [4, 
5]. Compliance to the plan, not the type of plan, is what produces weight loss [6]. What is 
really necessary is a 500 to 600 kcal (2100 to 2500 kJ) energy deficit and a plan that starts 
by making small changes to a patient’s habitual consumption. Such changes may include 
decreases in portion size, a reduction in fat (and in particular saturated fat), possibly an 
increase in mono-unsaturated fat, a reduction in sugar-sweetened beverages and a low 
glycaemic index diet. An increase in protein in the diet may increase satiety. Any changes 
must be made specifically in the context of the patient’s habitual diet. It is useful to keep 
food logs at regular intervals to check compliance and to use as a tool to suggest further 
changes in intake or eating patterns.
Physical activity
The term ‘physical activity plan’ is preferred to ‘exercise’, because the prescribed plan will 
include both planned exercise as well as incidental activity. A formal prescription of such 
a plan does produce greater compliance. Activity helps maintain lean mass and because 
of the increased energy deficit it promotes weight (kg) and fat mass loss. A simple initial 
approach is to use a physical activity questionnaire, determine how much time is spent 
walking or in specific exercise and perhaps suggest the use of a pedometer to get an activity 
baseline.
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The activity prescription itself should be specific to the patient. It may include increased time 
walking, more incidental activity (taking an active option), and/or specific exercises, gym 
programs or training, or involvement in sport. For diabetes prevention, supervised exercise 
sessions have been shown to be part of all-effective programs. It is good to remember that 
the greater the patient’s weight, the fewer ‘steps’ they have to do to lose weight. Activity 
should be monitored and the amount done recorded. Again this will help in assessment of 
compliance and will also be a tool for increasing the amount of activity performed.
Increased activity alone (as a weight-loss program) does not produce a great deal of weight 
loss. It may affect fat distribution [7, 8] but, for reasonable weight loss to ensue, activity 
must be combined with an eating plan [9].
Behaviour modification
The use of food and activity logs is part of behaviour modification. Another log that may 
be useful is one for mood, particularly at time of eating, as well as general affect. Cognitive 
behaviour therapy may be useful, particularly for optimising weight maintenance. Other 
techniques are those of cognitive restructuring, motivational enhancement therapy, 
psychological support and counselling. There are many techniques that may be used but to 
describe these in any detail is beyond the scope of this chapter. The techniques utilised need 
to be individualised to the patient’s situation and life stage, so there really is no ‘standard’ 
program – rather, a series of techniques used when necessary [10].
An effective lifestyle program must contain some or all of these elements, and though 
patient education alone is not effective in producing weight loss, it too is a part of a 
successful program. A multidisciplinary team providing care is essential. Regular visits (at 
least fortnightly initially and then at longer intervals) are important. Weight regain does 
tend to recur, particularly in the second year of a program and it is at this stage that there 
needs to be further research on the effect of repeated, brief acute interventions, the use of 
pharmacotherapy for maintenance, and/or the use of very low energy diets (VLEDs).
If the lifestyle program is not successful, with goals not being attained, then adjunctive 
therapy should be considered. Such consideration should begin early in any program, say 
at one month, with reconsideration at regular intervals.
Adjunctive therapy
Very low energy diets (VLEDs)
Such formulations are effective at producing early weight loss [11], although after a time 
(two to three years) they appear to produce no more weight loss than a standard lifestyle 
program. However if their use is continued (as one to two meal replacements per day) 
then significant weight loss can be both achieved and maintained [12]. These diets tend 
to contain 500 to 800 kcal/day and the necessary vitamins and micronutrients. Early 
formulations did not contain high-quality protein and a number of deaths ensued, but 
these difficulties have been addressed and current formulations are safe, provided they are 
used according to protocol, and preferably under medical supervision [13].
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These formulations are available as shakes, soups and bars, and in most countries they are 
classified as ‘Foods’. They may be used as a full meal replacement protocol (every meal a 
VLED) or as a partial protocol (one to two meals a day as a VLED). The full protocol is best 
performed under clinical supervision, particularly if the patient has diabetes or cardiac 
disease. The full protocol has been used as the ‘control treatment’ in randomised trials of 
bariatric surgery and quite reasonable weight losses, of the order of 15% or more of initial 
body weight, are obtained.
Initial full-meal replacement protocols usually run for 12 to 16 weeks though under 
supervised conditions there is no reason why they should not be used for longer. They can 
be used as one to two meals per day to help maintain weight loss. They are generally used 
prior to bariatric surgery [14] to reduce some weight and to reduce fat in the liver (which 
makes surgery easier).
Pharmacotherapy 
The relatively limited success of lifestyle interventions has driven the search for effective 
anti-obesity drugs. Drug treatment of obesity is driven by similar principles for 
pharmacotherapy of other chronic diseases: it needs to be effective and safe (particularly 
as it will need to be used long term), acceptable to patients and affordable [15]. While 
the physiological control of body weight theoretically provides many targets (satiety, 
nutrient absorption and energy expenditure), in practice it has proven hard to find safe 
and effective drugs and regulatory authorities such as the Food and Drugs Administration 
in US, European Medicines Evaluation Agency and Therapeutics Goods Administration 
in Australia, have set guidelines and standards of evidence for efficacy and safety that have 
proven a barrier to new drug development.
Drugs available in the past 20 years but no longer licensed
Amphetamine-like drugs with predominant actions of enhancing brain dopamine 
pathways included phentermine and diethylpropion. They produced anorexia (rather than 
satiety) and had some CNS stimulant properties. Although they produced weight loss of 
about 5%–10% they were not evaluated according to contemporary standards for clinical 
trials. Phentermine is available and used short term in the US, Asia and Australia, but 
not in Europe. The fenfluramines developed in the 1980s were effective satiety-enhancing 
drugs that acted mainly through enhancing central serotoninergic neuronal transmission 
(by both release and reuptake inhibition of serotonin). However they were associated with 
pulmonary hypertension and cardiac valve abnormalities (especially when combined with 
phentermine) and withdrawn from use in 2004. The endocannaboid receptor (CB1 receptor) 
was identified as an attractive target since it had long been known that stimulation of this 
receptor led to hunger; a number of selective CB1 receptor blockers were developed in the 
early 2000s, with rimonabant being licensed in Europe on the basis of four clinical trials 
that showed it could produce weight loss of about 10% absolute, 5.6 kg placebo-subtracted, 
and that efficacy was maintained over at least two years. Furthermore rimonabant use was 
associated with metabolic improvements of lipids and glycaemic control. However shortly 
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after approval it became clear that there was an unacceptable incidence of depression and 
suicidal ideation with the drug that led to its withdrawal [16].
Sibutramine, a selective serotonin and norepinephrine-uptake inhibitor had been licensed 
and in use worldwide since the 1990s. It produced placebo-subtracted weight loss of about 
5% over one year, but appeared to have greater efficacy when combined with intensive 
lifestyle interventions: in one trial an average 12∙1 kg weight loss compared to five kilograms 
with sibutramine alone. Concerns remained that the drug had unwanted and potentially 
dangerous sympathomimetic effects that could raise blood pressure and pulse, so at the 
demand of the European Medicines Agency the Sibutramine Cardiovascular Outcomes 
(SCOUT) trial assessed the efficacy of sibutramine in reducing myocardial infarction, 
stroke, and cardiovascular mortality in 11 000 obese and overweight patients. In order to 
produce enough cardiovascular endpoints, patients with existing cardiovascular disease 
and diabetes and at high risk for future events were recruited (a population that would have 
been excluded according to the drug licence). The trial reported that despite well-sustained 
weight loss, there was an excess of non-fatal cardiovascular events in the subjects receiving 
sibutramine for up to four years [17] and this led to the withdrawal of the drug.
Current drugs licensed for obesity treatment
In 2011 orlistat, a pancreatic and intestinal lipase inhibitor, was the major drug licensed 
for obesity treatment. It produces malabsorption of about 30% of ingested dietary fat. Its 
use is limited by gastro-intestinal side effects (steatorrhea, flatus, urgency of defecation 
and sometimes even faecal incontinence) such that unless subjects are on a low-fat diet 
(maximum 90 gm fat daily) it is unlikely to be tolerated. In this setting the drug can produce 
an approximate 300 kcal/day energy loss through undigested fat. In a meta-analysis of 11 
placebo-controlled trials of one year in over 6000 overweight or obese patients, orlistat 
120 mg thrice daily reduced weight by about 3% more than placebo, with 21% reaching 
a 5% loss, and 12% a 10% or greater weight loss. Orlistat has favourable effects on blood 
pressure, lipids and blood glucose. In some countries orlistat is available at a dose of 60 mg 
thrice daily either over the counter or through pharmacist prescription [18–20].
Phentermine is available in Australia, the US and Asia. It is an older drug with a central 
action on appetite. There are no long-term studies, but it has been shown to be effective 
short term and may be used to help produce or maintain weight loss. Further studies are 
really needed to define its place in obesity management.
Drugs producing weight loss licensed for other indications
The glucagon-like peptide 1 (GLP-1) incretin analogues exenatide and liraglutide are both 
licensed for use as hypoglycaemic drugs for treating type 2 diabetes, and they produce 
a weight loss of two to four kilograms. GLP-1 agonists have complex modes of action 
on weight loss that include delayed gastric emptying, and both direct, and indirect via 
the vagus nerve, stimulation of central nervous system satiety pathways. The drug has to 
be given by subcutaneous injection. Liraglutide given at higher doses than used to treat 
diabetes is in clinical trials as a weight-loss agent in non-diabetics. Early results have shown 
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body weight losses of about 10% associated with marked metabolic and cardiovascular 
improvements sustained for two years [21].
Currently much focus is on combining drugs at low doses to produce synergistic weight-
loss effects while minimising side and unwanted effects [22]. Combining naltrexone (an 
opioid receptor antagonist) with bupropion (an antidepressant) showed synergistic effects 
on the firing of hypothalamic pro-opiomelanocortin neurons in mice. In a trial of nearly 
2000 overweight and obese subjects the highest dose combination produced weight loss of 
6.1% at one year compared to 1.3% on placebo. Side effects were mainly gastrointestinal, 
but there were transient increases in blood pressure with less fall than might have been 
expected from the weight-loss achieved [23].
The anti-epilepsy drug topiramate has been combined with phentermine and also 
investigated in clinical trials. In nearly 2500 patients the highest dose combination 
produced a weight loss after 56 weeks of just under 10% compared to 1.2% of those on 
placebo. Dizziness, depression and anxiety were the most common side effects and will 
need further evaluation before the drug will be licensed. 
Bariatric surgery
Bariatric procedures aim to produce and maintain weight loss by altering energy balance 
primarily by reducing food intake and mitigating the physiological changes that drive 
weight regain. Most guidelines recommend that bariatric surgery be considered for those 
with a BMI above 35 kg/m2 with an obesity-related comorbidity, or above 40 kg/m2 in those 
without. A multidisciplinary team including surgeon, anaesthetist, physician, dietitian, 
specialist nurse and psychologist or psychiatrist is needed to provide optimal care.
Four procedures are most commonly performed, in modern practice all laparascopically: 
Roux-en-Y gastric bypass, adjustable gastric banding, sleeve gastrectomy and biliopancreatic 
diversion (Figure 1), with considerable variation between countries in the preferred 
procedures.
Roux-en-Y gastric bypass creates a small gastric remnant that empties directly into the 
transposed jejunum, bypassing the main body of the stomach, duodenum and proximal 
jejunum. Although the procedure was initially thought to produce weight loss by both 
restriction and malabsorption of food intake, it is clear that the impact of food entering 
rapidly into the distal jejunum is associated with the rapid release of gastrointestinal 
peptide satiety hormones including GLP-1 and Peptide YY (PYY), as well as decreasing 
the orexigenic hormone ghrelin, released from the stomach. Other factors postulated to 
produce weight loss include altered bile salt secretion and altered gut microbiota. Patients 
require lifelong vitamin B12 and vitamin D replacement. Weight losses average 35%–40% 
at five years.
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Figure 1. Types of bariatric surgery, shown schematically from top left to bottom right: 
normal stomach, adjustable gastric band, gastric bypass, sleeve gastrectomy.
Adjustable gastric bypass is a simpler procedure in which an adjustable silastic band is 
placedaround the proximal fundus of the stomach to leave a pouch of about 15 to 30 ccs. A 
tube leads from the band to a port positioned subcutaneously through which saline can be 
injected to tighten (or loosen) the band. Frequent adjustments of band filling are required 
and success is critically dependent on this process as well as the patient’s willingness and 
ability to adapt their diet and respond to the sense of fullness that the band produces. 
Weight losses average 25%–30% at five years. Sleeve gastrectomy was originally introduced 
as a first step for patients at too high a surgical risk for a Roux-en-Y procedure, with the 
intention to convert the gastrectomy to a bypass at a second operation after the patient 
had lost some weight. The finding that sleeve gastrectomy led to similar weight loss and 
metabolic benefit as the full Roux-en-Y procedure led to enthusiasm for this technically 
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simpler procedure, but more recent evaluation suggests weight-loss and metabolic 
improvement are less durable.
Bilio-pancreatic diversion with or without a duodenal switch procedure is a major 
malabsorptive procedure that is not widely performed and has been less well evaluated 
than other procedures. Although weight loss may be 40%–60%, nutritional complications 
are frequent.
The most compelling data for the success of bariatric surgery at producing weight loss and 
improving the clinical outcomes for obese patients comes from the 15-year follow-up data 
of the Swedish Obese Subjects study (SOS) [24]. This was a case controlled study, and the 
surgical techniques were not as advanced as performed nowadays. The persistent weight 
loss in the surgical groups was associated with a much reduced mortality: the unadjusted 
overall hazard ratio was 0.76 in the surgery group (P = 0.04), as compared with the control 
group, and the hazard ratio adjusted for sex, age and risk factors was 0.71 (P = 0.01). Other 
studies have confirmed that bariatric surgery is associated with reduced all-cause mortality 
including deaths from cardiovascular disease, diabetes and cancer.
Bariatric surgery has important benefits in patients with type 2 diabetes that extend beyond 
weight loss [14]. Up to 80% of people with type 2 diabetes may experience remission of 
their diabetes (normoglycaemia without the need for hypoglycaemic medication), the 
exact remission rate being determined by the type of surgery and the duration of diabetes 
prior to surgery. Systematic reviews suggest that about 60% will have remission after gastric 
banding (and that the remission is of slower onset and more closely related to weight loss) 
compared to 80% after Roux-en-Y bypass, and 95% after bilio-pancreatic diversion. The 
International Federation of Diabetes position statement in 2011 concludes that bariatric 
surgery: a) constitutes a powerful option to ameliorate diabetes in severely obese patients, 
often normalising blood glucose levels, reducing or avoiding the need for medications and 
providing a potentially cost-effective approach to treating the disease; b) is an appropriate 
treatment for people with type 2 diabetes and obesity not achieving recommended treatment 
targets with medical therapies; c) should be an accepted option in people who have type 
2 diabetes and a BMI >35; and even d) an alternative treatment option in patients with a 
BMI between 30 and 35 when diabetes cannot be adequately controlled by optimal medical 
regimen, especially in the presence of other major cardiovascular disease risk factors [25].
Though it is effective for weight loss, the complications of bariatric surgery are significant 
[26]. The mortality risks of surgery itself are <0.5% overall, although the risks for those 
individuals with pre-existing cardiovascular disease or other morbidity may be substantially 
higher. Short-term complications are substantially lower with gastric banding compared 
to other procedures, but later complications are common. Re-operation rates for ‘slipped’ 
bands or erosion of the band through the stomach wall may occur in as many as 30% of 
banded patients after five years and a third may fail to lose or maintain weight loss [27]. 
Other longer-term complications in gastric bypass patients include strictures, excessive 
weight loss, and hypoglycaemic dumping. The latter appears to be driven by excessive 
incretin, and hence insulin responses to (inappropriate) high-carbohydrate meals.
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Figure 2. Weight trajectories from Swedish Obese Subjects study. Source: Sjöström L, 
Narbro K, Sjöström DC, Karason K, Larsson B, et al. (2007). Effects of bariatric surgery on 
mortality in Swedish obese subjects. The New England Journal of Medicine, 357(8): 747.
While bariatric surgery has much to offer, for optimal results highly experienced surgeons 
doing high volumes of surgery, in patients who have an adequate understanding that 
surgery is an aid not a ‘quick fix’ to weight loss, and with excellent nutritional support and 
more general psychological counseling are needed.
Devices 
There are a number of devices which have been used to manage obesity. One in relatively 
common use is the intragastic balloon. This is placed endoscopically, inflated with fluid, 
and for the first week after placement the patient stays on VLEDs until the balloon becomes 
fixed. This device restricts eating and in a recent trial with obese subjects we have shown 
weight losses of 14% of initial body weight at six months compared to 4.8% in controls who 
were treated with a lifestyle program [28]. After the balloon is removed at the six month 
time point, there is some weight regain but at 12 months there is still more weight lost by 
the ‘balloon’ group (some 9% of initial weight), whilst those in the control group maintain 
their weight loss. There are side effects of the balloon, especially cramping and vomiting, 
but those treated this way have a significant increase in their measured quality of life. Other 
devices being investigated include endoduodenal sleeves (a plastic sleeve which lines the 
duodenum) and gastric pacemakers. These too need to be placed endoscopically.
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General issues
Obviously many of those overweight or obese will already have an obesity-related 
comorbidity, either metabolic or mechanical (these are discussed elsewhere in this 
volume). These problems should be treated actively, but at the same time a weight-loss 
program should be instituted and conversely during a weight-loss program there should 
be active, effective treatment of such comorbidities. Weight loss can help improve these 
medical problems [29] and also reduce the medications required to treat them [30], as well 
as improving quality of life.
At the same time care should be taken to not use, or minimise the use and dose of, drugs 
which may cause weight gain. These include antipsychotics and antidepressants, steroid 
therapy, anticonvulsants (especially valproate) and medications used to manage diabetes. 
Where possible an alternate drug which has no effect on weight, or which can help weight 
loss should be chosen. For example, use of an SSRI such as fluoxetine in depression can 
promote weight loss, topiramate is an anti-epileptic which promotes weight loss [31], 
metformin may produce or assist with weight loss and some of the newer anti-diabetic 
agents, such as the GLP1 agonists, promote weight loss.
Maintenance of weight loss
This is a vexed issue. Within three to five years of completed and effective weight-loss 
programs most of the weight loss will have been regained, though there is increasing 
evidence these programs can be effective [32]. Even following bariatric surgery, where there 
is substantial weight loss which can be maintained for years, there tends to be a slow regain 
(though not to initial weight). This regain is due to ‘relaxation’ of the lifestyle program and 
is caused by underlying physiological drivers, such as elevated appetite hormones causing 
increased hunger, which force a reversion to old eating patterns (as an example).
There are some individuals who lose weight and do keep it off for years. These individuals 
undertake high levels of physical activity, eat breakfast and regular meals, a diet that is low 
in fat, and they self monitor which is a way of catching ‘slips’ early and correcting them. 
However, this type of response is not the common one.
Does that mean weight-loss programs are always failures and therefore should not really be 
attempted? The answer to this is a resounding ‘no’ on at least two counts. Firstly, weight loss 
does have an effect on many aspects: the control and prevention of disease, greater mobility, 
better quality of life and so on. There is even evidence from the diabetes prevention trials 
that a beneficial metabolic effect, the so-called metabolic memory, persists for years after 
the program has ceased and even if weight is regained.
Secondly, most of the reported weight-loss ‘failures’ are the follow-up of a single intervention. 
It is important that it is realised that the struggle against the issue of excess weight is a 
chronic, lifelong one. Programs need to be developed which include regular follow-up, 
which use pharmacotherapy to maintain loss, and have acute interventions if there is a 
small amount of regain (in our clinic we use a regain of three kilograms as the trigger for a 
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more intense effort). The US-based Look AHEAD program in people with type 2 diabetes 
is one such example [32]. Multidisciplinary chronic care programs will become even more 
necessary as the cohort of those who have had bariatric surgery increases – this group will 
need such lifetime follow-up. With the development of these long-term programs there 
must be research on effectiveness and over time, long-term weight loss and maintenance 
will be achieved.
Management of obesity in children and adolescents: whom and when to treat?
Presentations to healthcare settings
Children and adolescents who are overweight or obese attend both primary and tertiary 
healthcare settings more frequently than might be expected from the background 
prevalence of this condition [33–36]. This is probably because of the health complications 
linked to their weight status. However, they rarely present to the doctor specifically for the 
problem of obesity. In a large random sample of Australian general practice surgeries, the 
BEACH study, 29.6% of two- to 18-year-olds were overweight or obese (11.4% overall were 
obese), compared with a background population prevalence of 23%–25% (5%–8% obese). 
Unfortunately, these patients are unlikely to have the problem of obesity addressed by the 
clinician. In the BEACH study, only 1:60 of those who were overweight or obese had any 
form of management provided for this issue [34].
Why might this situation be? While Australian general practitioners (GPs) state that 
they are committed to dealing with the consequences of obesity, they also cite a range of 
barriers to managing it, including inadequate time and reimbursement, an apparent lack 
of effective interventions and support services, low levels of parent or patient motivation, 
the complexity and sensitivity of the issue, and the need for further training [37]. Families 
themselves are somewhat circumspect about the role of GPs on this issue and do not see 
GPs as the primary source of advice about management of obesity in young people [38].
Indicators for treatment
So, should children and adolescents affected by obesity seek or receive treatment, and, if 
so, where? As a general principle, assessment and treatment is especially warranted for the 
following individuals [39–42]:
•	 Those who are moderately to severely obese
•	 Adolescents
•	 Those with obesity-associated complications, such as insulin resistance, obstructive 
sleep apnoea, psychosocial distress, fatty liver disease, cardio-metabolic risk factors, or 
orthopaedic complications
•	 Those with a high risk family history, such as parents, grandparents, siblings or aunts/
uncles with type 2 diabetes, premature heart disease, a history of bariatric surgery, 
obstructive sleep apnoea, hypertension or dyslipidaemia
•	 Those from a high-risk ethnic group, where cardio-metabolic complications are more 
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common, such as Aboriginal and Torres Strait Islanders, Maori and Pacific people, 
those from Mediterranean or Middle-Eastern countries or the Indian subcontinent, 
and native Americans.
Where should treatment be provided?
Given the high prevalence of child and adolescent obesity in most Westernised, and rapidly 
Westernising, countries, and its chronicity, coordinated models of care for health service 
delivery are needed. However, no country has yet established a cost-effective model of care 
for obesity management. One potential approach is that adapted from the UK National 
Health Service [43] and Kaiser Permanente [44] chronic disease pyramid of care. This is 
based upon a tiered level of service delivery relating to severity of disease. 
Ideally, the vast majority of those affected by the problem of obesity should be managed via 
self-care or family-based care, with support from GPs or community-based health service 
providers. Such patients should be offered healthy lifestyle counselling or community-based 
group programs. The next stage of management involves more targeted recommendations 
for behavioural change, supported by involvement of allied health professionals, such 
as dietitians, or, indeed, a multidisciplinary team of therapists. The final stage, which is 
offered to children and adolescents with severe obesity, is provided by a specialist team 
and may include provision of pharmacotherapy, very low energy diets, or even bariatric 
surgery. The patient’s age, severity of obesity and obesity-associated complications, and 
level of engagement with, and success of, previous interventions, should determine which 
stage of therapy is offered. 
Unfortunately, such a staged approach to care is yet to be resourced or implemented widely 
in countries such as Australia. In reality, most children and adolescents who are affected 
by obesity will be managed by their GP, possibly with some involvement of a practice 
nurse or dietitian. Certainly, those children or adolescents who have severe obesity should 
be assessed, and have their care coordinated, by a paediatrician or adolescent physician, 
ideally with involvement of a multidisciplinary team of other therapists.
Lifestyle treatment
The mainstay of treatment of obesity in this age-group, as in adults, is lifestyle change. 
What is the evidence for this? 
The 2009 Cochrane review on the treatment of child and adolescent obesity included 64 
randomised controlled trials [45]. No one specific treatment program was recommended 
over another; however, positive outcomes were identified in several studies. A meta-
analysis of several studies showed that family-targeted lifestyle intervention, involving 
various combinations of dietary, physical activity and behaviour modification, led to a 
significantly greater reduction in BMI or BMI z-score (ie BMI adjusted for age and sex) 
at six months than ‘standard care’. For children aged less than 12 years there was a modest 
average reduction of 0.06 in BMI z-score, and in adolescents there was an average reduction 
of just over three BMI units.
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However, many published studies are limited by varying attrition rates, small sample sizes, 
different measures of change in body size, and lack of assessment of other outcomes (for 
example, broader medical, psychosocial and behavioural outcomes). And they have typically 
involved fairly homogeneous patient samples managed in a tertiary care setting. Although 
recent trials are addressing some of these issues, much of the evidence to support effective 
intervention may not be readily generalisable to other clinical settings. For example, ‘real-
world’ obesity clinics are usually less well resourced than programs in clinical trials, and 
patients seen in such clinics may be quite different from those who volunteer for trials. 
They may have more social disadvantage, or have psychosocial complications and other 
problems that make adherence to treatment more difficult. Not surprisingly, therefore, 
studies in clinical practice have demonstrated poorer results than in formal clinical trials 
[46]. Nevertheless, the broad principles of management are well recognised and are 
outlined in Box 1. 
Box 1. Principles of obesity management in children and adolescents 
•	 management of obesity-associated comorbidities
•	 family involvement
•	 a developmentally appropriate approach
•	 long-term behaviour modification
•	 dietary change
•	 increased physical activity
•	 decreased sedentary behaviours 
•	 consideration of the use of pharmacotherapy and other forms of non-conventional 
therapy
•	 plan for longer-term weight maintenance strategies.
Effective management of obesity-associated comorbidities, such as sleep apnoea, 
dyslipidaemia, hypertension, non-alcoholic fatty liver disease or type 2 diabetes mellitus, 
is vital. Ideally, patients should be co-managed, in a coordinated way, by relevant specialist 
teams. In all cases, effective weight management should be a key element of the treatment 
of the comorbidity. Further discussion of the management of these comorbidities is beyond 
the scope of this review.
Family focus 
Many clinical trials show that family-based interventions can lead to long-term relative 
weight loss (that is, from two to ten years) [45, 47–50]. Parental involvement is vital when 
managing obese younger children in particular [45, 48, 51–53]. This makes sense, as parents 
are normally the people in the family who are responsible for the food and physical activity 
environment, such as buying and cooking food, the types of routines around meals and 
meal times, rules around TV viewing and bed-time, role-modelling of eating and activity 
behaviours, and the use of the family car.
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A developmentally appropriate approach 
The developmental age of the patient – whether they are pre-adolescent, or adolescent, or, 
indeed, whether they have a developmental disability – will influence whether the patient 
per se is involved in treatment, and the type of parental engagement. A different approach 
is usually needed for pre-adolescent children compared to adolescents. 
Pre-adolescent children 
When managing pre-adolescent children, a parent-focused intervention, without direct 
engagement of the child, appears to have better outcomes to a child-centred approach [50, 
54]. Obese children aged six to 11 years and their parents were randomly assigned to either 
parent-only group sessions (with an emphasis on general parenting skills), or child-only 
group sessions. At one and seven years follow-up from baseline, a significant reduction in 
overweight was observed in the parent-only group compared with the child-only group. At 
one year, there was a 14.6% reduction in overweight in the parent-only group versus 8.1% 
in the child-only group (p <0.03), with a nine times greater dropout rate in the child-only 
group [50]. At the seven-year follow-up, 60% of the children in the parent-only group, 
versus 31% of those in the child-only group, were classified as non-obese [54]. These and 
other studies suggest that when treating pre-adolescent children with obesity, therapy 
sessions involving the parent or parents alone, without the young child being present, 
could be the most effective.
Adolescents
There are fewer studies looking specifically at treatment of adolescents affected by obesity. 
The previously mentioned 2009 Cochrane review included 27 trials involving participants 
aged 12 years and older [45]. Twelve studies used behavioural lifestyle modification, ten 
involved drug therapy, three used physical activity, and two involved diet. Most included 
studies were of high intensity and were offered in secondary or tertiary level care settings. 
Many offered separate sessions for adolescents and parents. In clinical practice, it may be 
useful to have at least some of the session time just involving the adolescent and therapist, 
engaging the parent later.
Behaviour modification
Behaviour modification in weight management includes a set of techniques employed 
to change thought processes and actions associated with eating, physical activity and 
sedentary behaviours [55]. Many trials of obesity management in children and adolescents 
have included a behavioural component, although these are often poorly described. In 
general, the greater the range of behaviour change techniques used, the better the weight 
outcomes [48]. Goal setting, stimulus control and self-monitoring are three key behaviour 
change techniques used. 
Goal setting can include performance goals (such as changing eating or activity behaviours) 
or outcome goals (such as specific weight loss). An example of a well-specified goal is:
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I will not buy any biscuits, chocolates or other high-fat foods during the weekly shopping. 
In order to make this easier, I will leave the children at home and shop on my own. If the 
children ask for junk food, then I will offer yoghurt or fruit instead.
Considerable session time may be required to set and review behaviour change strategies 
with families and young people [56].
Stimulus control refers to modifying or restricting environmental influences to aid weight 
control. The broader environment, whether at home, school or beyond, has a profound 
influence on a person’s decisions around eating, physical activity or sedentary behaviours. 
Although many of these environmental influences are beyond the scope of an individual or 
family to change (for example, food marketing or food pricing), many opportunities exist 
for families to implement stimulus control in the everyday environment. Examples include: 
not eating in front of the television; not having television or other screens in bedrooms; 
using smaller plates, bowls and spoons; and not storing unhealthy food choices in the 
house [47].
Self-monitoring is the detailed recording of a specific behaviour and can contribute to 
better weight control in children and adolescents [57]. This self-monitoring can take 
several forms: use of a food diary, television use diary, daily pedometer measurement of 
physical activity, or weekly weighing, as examples [58].
Motivational interviewing is a ‘client-centred, directive method for enhancing intrinsic 
motivation to change by exploring and resolving ambivalence’ that is increasingly being 
used in obesity management [59]. It requires an empathetic and collaborative therapist who 
responds to the patient’s (or parent’s) ambivalence to change in a nonjudgmental fashion. 
In addition, the therapist uses open-ended questions and reflective listening techniques to 
help direct communication toward change in behaviour [41, 59, 60]. 
Dietary change and eating behaviours 
A 2006 systematic review of paediatric obesity trials showed that interventions containing 
a dietary component were effective in achieving relative weight loss [61]. The Traffic Light 
(also known as the Stop Light) diet was the most commonly used diet intervention. Briefly, 
in the Traffic Light diet, foods are colour-coded to indicate those to be eaten freely (green) 
and those to be eaten more cautiously (amber and especially red) [55]. Although food or 
kilojoule exchange programs were also identified as common dietary interventions in the 
above review, only one trial compared diets of varying macronutrient composition. Since 
then, a substantial body of evidence has accumulated on the effects of diets with different 
macronutrient profiles on weight loss or maintenance, especially in adults, with results 
tending to favour diets proportionately higher in protein relative to carbohydrate and with 
a low glycaemic index [62–66]. For example, results published in 2010 from the DiOGenes 
randomised controlled trial compared the effect of five ad libitum diets (with variations 
in glycaemic index and protein content) on body composition in European children: a 
low protein–high glycaemic index diet increased body fat, whereas overweight or obesity 
decreased in the high protein–low glycaemic index diet group [65]. 
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What recommendations should currently be given? Dietary interventions should follow 
national nutrition guidelines and have an emphasis on the following [47, 52, 66–68]:
•	 regular meals
•	 eating together as a family
•	 choosing nutrient-rich foods that are lower in energy and glycaemic index
•	 increased vegetable and fruit intake
•	 healthier snack food options
•	 decreased portion sizes
•	 promotion of water as the main beverage, and a reduction in sugary drink intake
•	 involvement of the entire family in making the change to a sustainable and healthy 
food intake.
In advising patients and families on dietary change, is there a potential risk of an eating 
disorder developing? Although most people with obesity do not have binge-eating 
disorder, the more severe the obesity, the more likely the patient is to have binge-eating 
disorder [69]. In addition, obesity in childhood, or parental obesity, is a risk factor for later 
bulimia, and overweight adolescents are more likely to use a range of unhealthy behaviours 
to binge-eat [70]. On the other hand, evidence indicates that professionally run paediatric 
obesity programs do not increase the risk of disordered eating and might, indeed, improve 
psychological wellbeing [71]. For these reasons, Hill has highlighted the need for ‘properly 
and expertly managed’ weight-control interventions to avoid the risk of an eating disorder 
[72].
Physical activity and sedentary behaviours 
Physical activity 
Involvement of children in a lifestyle program (for example, walking, running, cycling 
or swimming, based on the family’s preference) leads to greater reductions in percentage 
overweight at six months and 17 months when compared with a program of organised 
aerobic exercise involving the same prescribed level of energy expenditure [73]. A study of 
similar design, but including a third control group involved in calisthenics, and with follow-
up for ten years, showed that the lifestyle and aerobic exercise programs were superior in 
terms of percentage overweight reduction to the calisthenics control group [74].
A systematic review and meta-analysis of exercise interventions in overweight children 
and adolescents indicated that 155 to 180 minutes per week of supervised moderate-to-
high intensity physical activity (with or without an associated dietary intervention) was 
effective in reducing body fat, although the effects on body weight and abdominal fat 
were inconclusive [75]. In 2008, the effect of resistance training on metabolic fitness in 
children and adolescents was investigated in a systematic review of 12 trials, with eight 
of them targeting people who were overweight or obese [76]. Most of the interventions 
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included in that review involved circuit-type resistance training (moderate–high velocity, 
low–moderate load) involving machine weights. Unfortunately, limitations in study design 
and reporting prohibited definitive conclusions being established, but the beneficial effect 
of resistance training on health outcomes in adults was noted by the study authors. 
Sedentary behaviours 
Several studies and clinical guidelines address the issue of targeting sedentary behaviours. 
For example, in one study, 90 families of children aged eight to 12 years with obesity 
were assigned to different arms of a behavioural weight-control program in which either 
sedentary behaviours or physical activity were targeted, with two different levels of 
behaviour change being required. At two-year follow-up, similar improvements in aerobic 
fitness, body-fat percentage and percentage overweight were observed for all treatment 
arms, indicating that modifying sedentary behaviour is as effective as changing physical 
activity levels [77].
What recommendations can be given in terms of physical activity and reduction of 
sedentary behaviour? [39, 41–43, 45, 68]
•	 Increased physical activity may best result from a change in incidental or unplanned 
activity; for example, walking or cycling for transport, household chores, and playing 
with friends or family. 
•	 Organised exercise programs, such as playing sports, are also important. 
•	 Encourage children or adolescents to choose activities that they enjoy as these activities 
are more likely to be sustainable. 
•	 Limit television and other ‘small screen’ recreational viewing to less than two hours 
per day. This may be extremely challenging given the multiple types of screen-based 
activities available to young people. 
•	 Parental involvement is crucial if an increase in physical activity or a decrease in 
sedentary behaviour is to occur, including monitoring and limiting television use, 
role-modelling of healthy behaviours, and providing access to recreation areas or 
recreational equipment.
The Children’s Hospital Big Five
At the Children’s Hospital at Westmead, in Sydney, five strategies are emphasised when 
initially managing families with obese children or adolescents:
•	 Eat breakfast
•	 Choose water as your main drink
•	 Eat together as a family once a day, without the TV being on
•	 Limit TV and other ‘small screens’ to less than two hours per day
•	 Play, or be active, outside for at least 60 minutes each day.
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Adjunctive therapy
The evidence to guide the use of less orthodox treatment approaches – such as VLEDs, 
pharmacological therapy or bariatric surgery – in the treatment of severe obesity is more 
limited than for behavioural interventions. In general, such therapies should occur on the 
background of a behavioural weight-management program and be restricted to specialist 
centres with expertise in managing severe obesity. 
Very low energy diets (VLEDs)
As noted above, in adults, VLEDs are used to achieve rapid weight-loss prior to, or in 
conjunction with, the use of other longer-term treatment interventions [78]. VLEDs can 
also be associated with safe and substantial rapid weight loss in adolescents, typically 
producing six to 15 kg weight loss over three to 12 weeks [79–81]. However, most studies 
have been based on small sample sizes (less than 20 participants) and have lacked a control 
group, with very few studies having long-term follow-up [82]. To date, no randomised 
controlled trials have examined the effectiveness of a weight-management program 
incorporating initial VLED treatment in obese adolescents. The US Expert Committee 
recommended that VLEDs should ideally be used with severely obese patients who are 
managed by a multidisciplinary team in a tertiary care setting. They are not appropriate for 
use in young children.
Pharmacology in the treatment of childhood and adolescent obesity
The use of most anti-obesity agents (whether previously or currently available, or in 
development) is off label for children and adolescents. These agents should not be used in 
children and younger adolescents, as the risk outweighs the benefit and weight management 
depends primarily on parental control of the environment. There will be exceptional cases 
when anti-obesity agents might be trialled, with the appropriate consents in place. This 
will usually be for secondary obesity, for example hypothalamic hyperphagia syndromes. 
Somatostatin analogues have also been used with some success in children in this situation 
[83].
The choice of anti-obesity agents is limited and these should be prescribed as part of a 
lifestyle intervention, with diet and activity modification and behavioural intervention 
[84]. These agents may also be prescribed as part of bariatric surgery considerations and 
to enhance weight maintenance after weight loss in the older adolescent. As with adults, 
adolescents are likely to have unrealistic expectations of the benefits of drug therapy and 
these expectations may be greater in mid-adolescence when cognitive developmental stage 
limits their ability to understand the degree of weight loss possible. Adolescents generally 
have a very low tolerance for side effects and are likely to discontinue medication for 
tenuous reasons, including the lack of instantaneous benefit. 
There is some data on orlistat use in adolescents with greater weight loss compared to 
placebo [84, 85]. The side effects of flatulence, diarrhoea with urgency and faecal leakage 
are highly socially distressing and for most adolescents unacceptable. If they are prescribed 
orlistat they will simply not take it when they have a fatty meal away from home, which 
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may be when most higher calorie meals are consumed. For those who persist, careful 
monitoring of, and supplementation of, fat-soluble vitamins is important as adolescents 
appear more prone to deficiencies than adults.
Phentermine remains available in some jurisdictions and also for use in those over 12 
years old. It has adverse effects including palpitations, headaches, hypertension, insomnia 
and euphoric states. Phentermine also has the potential for abuse and should not be used 
in adolescents, many of whom already have binge-eating disorders and will be seeking 
medication to produce some anorexia. As depression is often present in this situation, 
fluoxetine might be beneficial as a centrally acting psychotropic which does not induce 
weight gain.
There is some evidence in children and adolescents that metformin may have a beneficial 
effect on body weight. It is the drug of choice in those with type 2 diabetes, who are 
invariably overweight, as it does not induce further weight gain. There is some evidence 
from small trials that metformin improves metabolic profile and reduces visceral fat in 
clinical scenarios where there is insulin resistance and weight gain, but not overt diabetes. 
These trials include the use of atypical anti-psychotics, such as risperidone, which are 
frequently prescribed for behavioural disturbances [86], and in medical conditions where 
physical activity is severely restricted [87]. The actual weight-loss results are less consistent. 
Metformin, also off label, may be advantageous in the obese adolescent female with the 
polycystic ovary syndrome and anovulatory bleeding or acanthosis nigricans. Both these 
conditions will improve and in some there may be a weight benefit, based on some small 
clinical trials. It is essential that a low start dose of metformin is chosen, 250 mg daily 
commencing with the evening meal. The dose should be built up to two grams over three 
to four weeks to minimise risk of the well-known side effects of abdominal pain and 
diarrhoea. Vitamin B12 levels should be monitored as the development of deficiency is not 
uncommon.
Puberty is a time where weight gain can accelerate in an overweight child or adolescent [88]. 
While it is clear from the previous discussion that there are no available pharmacotherapeutic 
agents to counter this, clinicians should carefully consider prescription of commonly used 
drugs which may further increase weight. Select if possible an oral contraceptive which 
contains one of the newer gestagens, such as desogestrel or drospirenone. Consider 
etonogestrel, rather than medroxyprogesterone acetate as a long-acting contraceptive 
preparation.
Bariatric surgery 
Bariatric surgery is a well-recognised form of therapy for adults with severe obesity, 
especially if medical therapy has failed [89]. What about its role in adolescents? Almost 
all of the literature in this area is of case studies or case series, with only one published 
randomised controlled trial to date [90].
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Evidence for bariatric surgery in adolescents 
A 2008 systematic review of bariatric surgery for adolescent obesity included studies 
that reported outcome data for patients under the age of 21 years (average age 16.8 years, 
range nine to 21) who were followed up for at least 12 months [91]. Nineteen papers were 
included, including eight studies of laparoscopic gastric banding, six studies of Roux-en-Y 
gastric bypass, and five studies of other surgical procedures. The laparoscopic adjustable 
banding procedures, with one to three years follow-up, had 95% confidence intervals for 
weight loss of –13.7 to –10.6 BMI units. No perioperative deaths were reported, and the 
main complication reported was the need for re-operation (for band slippage), which 
occurred in 8% of patients. For Roux-en-Y gastric bypass procedures, the mean weight loss 
was greater, with 95% confidence intervals of –17.8 to –22.3 BMI units, albeit over a longer 
period of follow-up (as the procedure has been established for longer). Some deaths were 
reported after this type of surgery. The most frequently reported complications related to 
protein-energy malnutrition and micronutrient deficiency. Note that none of the included 
studies in this systematic review was a randomised controlled trial, and hence the strength 
of evidence could only be classed as moderate to weak. However, these findings are similar 
to those seen in comparisons of bariatric surgery in adults [89].
After this review was published, the results of the first randomised controlled trial of 
bariatric surgery in adolescents with severe obesity became available in 2010 [90]. This 
study was undertaken in Melbourne and included 50 adolescents with severe obesity (BMI 
>35 kg/m2) aged between 14 and 18 years who were randomly assigned to receive either 
a supervised lifestyle intervention, involving reduced energy intake, increased physical 
activity and behaviour modification, or laparascopic adjustable gastric banding. By 24 
months, the surgical group had an average reduction in BMI of 12.7 units, versus 1.3 
units in the lifestyle group. The surgical group also had marked improvements in both 
cardiometabolic status and quality of life. However, eight operations (33%) were required 
in seven patients for revisional procedures. 
Guidelines on bariatric surgery 
In 2009, Australian and New Zealand consensus recommendations for bariatric surgery 
in adolescents were published by the professional bodies representing paediatricians, 
paediatric surgeons and bariatric surgeons [92]. The recommendations included the 
following:
•	 Patient: A minimum age of 15 years (or 14 years in exceptional circumstances); 
post-pubertal; presence of severe obesity (a BMI >40 kg/m2, although it should be 
considered in adolescents with a BMI >35 kg/m2 in the presence of severe obesity-
associated complications); presence of an associated severe comorbidity; persistence 
of obesity despite involvement in a formal multidisciplinary and supervised program 
of lifestyle modification and pharmacotherapy; the adolescent and family understand, 
and are motivated to participate in, the ongoing treatment, lifestyle change and review 
following surgery; the adolescent is able to provide informed consent for the surgery.
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•	 Surgical expertise and facilities: Surgery should be performed by an experienced 
bariatric surgeon affiliated with a team experienced in the assessment and long-term 
follow-up of the metabolic and psychosocial needs of the adolescent bariatric patient 
and family; the working party strongly recommended that publicly funded bariatric 
surgery be made available to those in need.
•	 Type of surgery: The majority recommendation was that the primary bariatric surgical 
procedure of choice for adolescents in Australia and New Zealand is laparoscopic 
adjustable gastric banding as it has good weight-based outcomes, has a low complication 
rate and is potentially reversible.
•	 Post-operative management and follow-up: Patients should be managed in the 
immediate post-operative period by a surgeon and bariatric surgical team with 
experience in adolescent care; adolescents will need more frequent post-operative 
follow-up than adult patients (eg four to six on weekly basis initially); patients will need 
ongoing care by a multidisciplinary team; issues such as improved fertility following 
weight loss, and hence the need for contraception, need to be considered; follow-up 
needs to extend beyond ten years, and ideally for the whole life.
One of the major challenges in Australia, as elsewhere, is how to ensure equitable access to 
such services for affected adolescents.
Long-term weight maintenance 
Few high-quality studies have reported long-term outcomes of treatment of childhood and 
adolescent obesity [45]. In those which have reported long-term outcomes, a high proportion 
of participants maintained a reduction in overweight from two to ten years from baseline 
without additional intervention after the initial treatment phase (weeks to months) [45, 67, 
93, 94]. However, in those who have undergone initial weight-management intervention, 
a period of further therapeutic contact (varying from four to 12 months) seems to slow 
weight regain [95]. At present, there is only limited evidence to guide the nature and type 
of weight-maintenance interventions in the child and adolescent age group. 
Conclusions
Obesity and overweight are common problems at most life stages. They produce many 
associated comorbidities and psychosocial issues contributing to substantial public health 
problems and costs. 
Treatment can be, and is effective. A lifestyle program should be associated closely with 
the treatment. Such a multidisciplinary program includes appropriate healthy eating, 
increased activity (both planned and incidental), behavioural techniques and counselling 
to help overcome ingrained habits and issues which may lead to weight gain. For children, 
the involvement of family in treatment is absolutely necessary. Finally, the program should 
not just be a ‘once-off ’ because weight is regained due to physiological systems which drive 
appetite after weight loss. The program should be reinstituted or reinforced at regular 
intervals and patients given a weight regain limit at which to return for a ‘booster’ program.
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A single treatment may be effective for those who need to lose a few kilos (5% or so 
of their initial weight), but for those with higher grades of obesity or complications of 
obesity, appropriate adjunctive therapies should be utilised and consideration given, when 
necessary, to bariatric surgery. 
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